Near-Infrared Emitting PbS Quantum Dots for in Vivo Fluorescence Imaging of the Thrombotic State in Septic Mouse Brain

Imamura, Yukio; Yamada, Shotaro; Tsuboi, Setsuko; Nakane, Yuko; Tsukasaki, Yoshikazu; Komatsuzaki, Akihito; Jin, Takashi

doi:10.3390/molecules21081080

Cited by 52 publications

(36 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing the quantum yield, functionality, and biocompatibility of SWIR fluorophores is an active focus of emerging research studies (24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41).…”

Section: Significancementioning

confidence: 99%

Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green

Carr

Franke

Caram

et al. 2018

Proc. Natl. Acad. Sci. U.S.A.

593

569

View full text Add to dashboard Cite

Fluorescence imaging is a method of real-time molecular tracking in vivo that has enabled many clinical technologies. Imaging in the shortwave IR (SWIR; 1,000–2,000 nm) promises higher contrast, sensitivity, and penetration depths compared with conventional visible and near-IR (NIR) fluorescence imaging. However, adoption of SWIR imaging in clinical settings has been limited, partially due to the absence of US Food and Drug Administration (FDA)-approved fluorophores with peak emission in the SWIR. Here, we show that commercially available NIR dyes, including the FDA-approved contrast agent indocyanine green (ICG), exhibit optical properties suitable for in vivo SWIR fluorescence imaging. Even though their emission spectra peak in the NIR, these dyes outperform commercial SWIR fluorophores and can be imaged in the SWIR, even beyond 1,500 nm. We show real-time fluorescence imaging using ICG at clinically relevant doses, including intravital microscopy, noninvasive imaging in blood and lymph vessels, and imaging of hepatobiliary clearance, and show increased contrast compared with NIR fluorescence imaging. Furthermore, we show tumor-targeted SWIR imaging with IRDye 800CW-labeled trastuzumab, an NIR dye being tested in multiple clinical trials. Our findings suggest that high-contrast SWIR fluorescence imaging can be implemented alongside existing imaging modalities by switching the detection of conventional NIR fluorescence systems from silicon-based NIR cameras to emerging indium gallium arsenide-based SWIR cameras. Using ICG in particular opens the possibility of translating SWIR fluorescence imaging to human clinical applications. Indeed, our findings suggest that emerging SWIR-fluorescent in vivo contrast agents should be benchmarked against the SWIR emission of ICG in blood.

show abstract

Section: Significancementioning

confidence: 99%

Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green

Carr

Franke

Caram

et al. 2018

Proc. Natl. Acad. Sci. U.S.A.

593

569

View full text Add to dashboard Cite

show abstract

“…Increasing the quantum yield, functionality, and biocompatibility of SWIR fluorophores is an active focus of emerging research studies. [24][25][26][27][28][29][30][31][32][33][34][35][36][37] Here we show that two commercially available dyes with peak emission in the NIR spectral region, including the FDA-approved contrast agent ICG, can function as SWIR emitters. Our findings are based on the observation that even though the emission spectrum of NIR dyes such as ICG or IRDye 800CW peaks outside of the SWIR spectral region, their fluorescence exhibits a broad shoulder with a spectral tail extending well into the SWIR that can be easily detected by modern SWIR cameras.…”

Section: Introductionmentioning

confidence: 64%

Shortwave Infrared Fluorescence Imaging with the Clinically Approved Near-Infrared Dye Indocyanine Green

Carr

Franke

Caram

et al. 2017

Preprint

View full text Add to dashboard Cite

Fluorescence imaging is a method of real-time molecular tracking in vivo that has enabled many clinical technologies. Imaging in the shortwave infrared region (SWIR, 1-2 µm) promises higher contrast, sensitivity, and penetration depths compared to conventional visible and near-infrared (NIR) fluorescence imaging. However, adoption of SWIR imaging in clinical settings has been limited, due in part to the absence of FDA-approved fluorophores with peak emission in the SWIR. Here, we show that commercially available NIR dyes, including the FDA-approved contrast agent indocyanine green (ICG), exhibit optical properties suitable for in vivo SWIR fluorescence imaging. Despite the fact that their emission reaches a maximum in the NIR, these dyes can be imaged non-invasively in vivo in the SWIR spectral region, even beyond 1500 nm. We demonstrate real-time fluorescence angiography at wavelengths beyond 1300 nm using ICG at clinically relevant doses. Furthermore, we show tumortargeted SWIR imaging with trastuzumab labeled with IRDye 800CW, a NIR dye currently being tested in multiple phase II clinical trials. Our findings suggest that high-contrast SWIR fluorescence imaging can be implemented alongside existing imaging modalities by switching the detection of conventional NIR fluorescence systems from silicon-based NIR cameras to emerging indium gallium arsenide (InGaAs) SWIR cameras. Using ICG in particular opens the possibility of translating SWIR fluorescence imaging to human clinical applications.

show abstract

“…It enables long-term tracking of cells with sensitive detections, but its limitations are a low penetration depth of only 1–2 mm, and low spatial resolution by scattered lights generated within tissues. In this regard, use of near-infrared (NIR) region (700–1000 nm) in OI is preferred to increase detection sensitivity [ 25 , 26 , 27 ].…”

Section: Imaging Modalitiesmentioning

confidence: 99%

Current Perspective on In Vivo Molecular Imaging of Immune Cells

2017

View full text Add to dashboard Cite

Contemporaneous development of improved immune cell-based therapies, and powerful imaging tools, has prompted growth in technologies for immune cell tracking in vivo. Over the past couple of decades, imaging tools such as magnetic resonance imaging (MRI) and optical imaging have successfully monitored the trafficking patterns of therapeutic immune cells and assisted the evaluation of the success or failure of immunotherapy. Recent advancements in imaging technology have made imaging an indispensable module of immune cell-based therapies. In this review, emerging applications of non-radiation imaging modalities for the tracking of a range of immune cells are discussed. Applications of MRI, NIR, and other imaging tools have demonstrated the potential of non-invasively surveying the fate of both phagocytic and non-phagocytic immune cells in vivo.

show abstract

Near-Infrared Emitting PbS Quantum Dots for in Vivo Fluorescence Imaging of the Thrombotic State in Septic Mouse Brain

Cited by 52 publications

References 42 publications

Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green

Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green

Shortwave Infrared Fluorescence Imaging with the Clinically Approved Near-Infrared Dye Indocyanine Green

Current Perspective on In Vivo Molecular Imaging of Immune Cells

Contact Info

Product

Resources

About